Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Respiratory Distress Syndrome (ARDS).

NCT04347967 is registered in ClinicalTrials.gov with Meridigen Biotech Co., Ltd. as lead sponsor.

NCT NCT04347967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04347967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Respiratory Distress Syndrome (ARDS).
Lead sponsor
Meridigen Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
January 1, 2024
Completion date
September 30, 2025
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome